While Felix remains management’s key focus, the company’s most advanced product under development is the RoXsta device, as in Rapid In Vitro Antioxidant Assessment.
Formerly called Rosa, RoXsta assesses oxidative stress in semen or blood. Oxidative stress is an underlying factor in conditions including Alzheimer’s diseases, diabetes, heart disease and pre-term births. This test is set to address many market gaps across multiple areas.
I must say, I'm surprised to read this, I thought the AI Port would be the most advanced. Aren't we supposed to get results on this in the very near future?
Media article: Memphasys accelerates commercial approval for sperm-separation device, page-6
Add MEM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.001(12.5%) |
Mkt cap ! $13.00M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $2.022K | 224.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2865000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 586468 | 2 |
View Market Depth
| Last trade - 13.46pm 17/09/2024 (20 minute delay) ? |
| MEM (ASX) Chart |